Nanomaterials as Drug Delivery Vehicles for Therapy of Parkinson's Disease

Parkinson's disease is a prevalent neurodegenerative disorder characterized by motor impairments and coordination difficulties. With a significant number of individuals affected worldwide, the need for innovative therapies is paramount. Nanomaterials have emerged as promising drug delivery vehicles to address the challenges in Parkinson's disease therapy. This article provides an overview of the potential of nanomaterials in improving therapeutic outcomes while reducing side effects. Current treatment options for Parkinson's disease primarily involve dopaminergic medications, such as dopamine agonists and levodopa. However, these treatments have limitations, including fluctuating efficacy and adverse effects. To overcome these challenges, nanomaterial-based drug delivery systems offer several advantages. Nanomaterials, including lipid-based nanoparticles, polymer-based nanoparticles, inorganic nanomaterials, and carbon-based nanomaterials, provide opportunities for targeted delivery, controlled release, and improved bioavailability. Lipid-based nanocarriers, such as liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), can enhance drug stability, encapsulation, and controlled release. Polymer-based nanoparticles and inorganic nanomaterials, such as mesoporous silica nanoparticles (MSN) and magnetic nanoparticles, offer targeted drug delivery and imaging capabilities. Carbon-based nanomaterials, such as carbon nanotubes and graphene, demonstrate unique properties for drug delivery applications.